Comparison of PET-based criteria of evaluation of response to immunotherapy in patients with advanced melanoma.

被引：0
|
作者：
Comito, Francesca [1 ]
Pagani, Rachele [1 ]
Aprile, Marta [1 ]
Dragonetti, Valentino [1 ]
Bonazzi, Norma [1 ]
Battisti, Giacomo [1 ]
Malizia, Claudio [1 ]
Nanni, Cristina [1 ]
机构：
[1] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21536
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced lung cancer or melanoma.
    Petrillo, Laura A.
    Zhou, Ashley
    Sullivan, Ryan J.
    Volandes, Angelo E.
    Greer, Joseph A.
    Temel, Jennifer S.
    El-Jawahri, Areej
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Stable disease or complete response? A critical evaluation of the radiologic response to immunotherapy in advanced melanoma
    Tietze, J.
    Heppt, M.
    Angelova, D.
    Berger, F.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 4 - 4
  • [33] A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
    Najjar, Yana
    McCurry, Dustin
    Lin, Huang
    Lin, Yan
    Davar, Diwakar
    Drabick, Joseph J.
    Neves, Rogerio Izar
    Ernstoff, Marc S.
    Puzanov, Igor
    Skitzki, Joseph J.
    Pingpank, James F.
    Holtzman, Matthew Peter
    Sander, Cindy
    Rose, Amy
    Kirkwood, John M.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Multiple primary malignancies among patients with advanced melanoma.
    Ebia, Matthew Isaiah
    In, Gino Kim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
    Shaked, Yuval
    Harel, Michal
    Issler, Eran
    Fremder, Ella
    Jacob, Eyal
    Dahan, Nili
    Bar, Haim
    Halaban, Ruth
    Sznol, Mario
    Sharon, Ofer
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A prediction model for response to immune checkpoint inhibition in advanced melanoma.
    van Duin, Isabella A. J.
    Verheijden, Rik Jasper
    van Diest, Paul J.
    van den Eertwegh, Alfonsus Johannes Maria
    de Groot, Jan Willem
    van Not, Olivier Jules
    Aarts, Maureen J. B.
    Van den Berkmortel, Franchette
    Blank, Christian U.
    Haanen, John B. A. G.
    Hospers, Geke
    Piersma, Djura
    van Rijn, Rozemarijn
    Van der Veldt, Astrid Aplonia Maria
    Vreugdenhil, Gerard
    Stevense-den Boer, Marion
    Boers-Sonderen, Marye J.
    Kapiteijn, Ellen
    Suijkerbuijk, Karijn
    Elias, Sjoerd G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Immunotherapy in advanced cutaneous melanoma patients
    Mackiewicz, Jacek
    Krokowicz, Lukasz
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (05): : 429 - 433
  • [38] PET-BASED PATHOLOGICAL TREATMENT RESPONSE EVALUATION IN RECTAL CANCER: PREDICT ION AND VALIDATION
    Janssen, M.
    Ollers, M.
    van Stiphout, R.
    van den Bogaard, J.
    Buijsen, J.
    Lambin, P.
    Lammering, G.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S68 - S69
  • [39] Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
    Hilke, Franz J.
    Sinnberg, Tobias
    Gschwind, Axel
    Niessner, Heike
    Demidov, German
    Amaral, Teresa
    Ossowski, Stephan
    Bonzheim, Irina
    Roecken, Martin
    Riess, Olaf
    Garbe, Claus
    Schroeder, Christopher
    Forschner, Andrea
    CANCERS, 2020, 12 (09) : 1 - 15
  • [40] Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
    Zwirtz, Kevin
    Hardt, Juliane
    Acker, Gueliz
    Baur, Alexander D. J.
    Pavel, Marianne
    Huang, Kai
    Brenner, Winfried
    Prasad, Vikas
    PHARMACEUTICS, 2022, 14 (06)
12345